Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
Context: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition: We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis: Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration. Conclusion: Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5. Indirect evidence to demonstrate that slow pot-prandial gastric emptying should not result in substantial gastric retention 12 hours after the last meal. (A) Six-hour gastric emptying tests (13C- octanoate breath for labeling solid meal components) analyzed using Wagner-Nelson equations were performed in 47 T2D subjects at baseline (black curves, with dotted lines indicating ± 95% confidence intervals). Results from subjects with substantially decelerated gastric emptying (at baseline or 10 weeks after initiating treatment with lixisenatide [20 µg/d] or liraglutide [1.8 mg/d]) are also shown. Gastric emptying curves between 6.5 and 12 hours after meal intake were interpolated assuming an exponential decay (from an initial plateau of 100%) based on the measurements during the initial 6 hours. Even those with slow gastric emptying achieved a gastric content near 0% by 12 hours, which would be a typical interval between a last meal (eg, dinner at 7 Pm) and an early procedure (endoscopy or general anesthesia) in the morning of the following day. Data used for display and modeling are from Quast et al (40). (B) Residual gastric content from food ingested on the previous day (or earlier) as visualized in the gastric antrum by upper gastrointestinal tract endoscopy (courtesy Diabetes Center Bad Lauterberg). Abbreviations: T2D, type 2 diabetes.](https://figures.cochat.ai/paper-figures/7d35bedb7ee940febd956b76a9173f53/clinical-consequences-of-delayed-gastric-emptying-with-glp-1-receptor-agonists-figure-5.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Activation of its GLP-1 component also delays gastric emptying, blunting postprandial glucose excursions and contributing to steadier overall glucose profiles [69].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The second is pharmacokinetic: GLP-1 agonists slow gastric emptying and so alter the absorption rate of oral drugs [47,120], while berberine inhibits enzymes and transporters at the same intestinal interface, so the two perturb one process from different directions [46,47].”
From Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review (2026) · cites this paper as [120]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This difference is believed to result from tachyphylaxis associated with prolonged GLP-1 RA use, leading to attenuation of the gastric emptying–delaying effect, which becomes more evident with long-acting formulations [32,33].”
From Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia (2026) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Based on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and…”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“Monnier at al reported that PPG is a dominant contributor to overall glycemia in T2D (as assessed by measurement of hemoglobin A 1c ), especially in well-controlled diabetes [calculated to contribute approximately 70% when hemoglobin A 1c is ≤ 7.3% (3)].”
InfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“…on the initial observation that low-dose intracisternal administration of GLP-1 reduces food intake acutely in rodents (52, 53), and similar findings of exogenous IV administration of GLP-1 in healthy humans (54), GLP-1RAs have been found to reduce body weight substantially in both T2D and obesity.”
Identifying and Avoiding Bias in Research
Pannucci, C. J., & Wilkins, E. G. (2010) · Plastic and Reconstructive Surgery · doi:10.1097/prs.0b013e3181de24bc · Cited by 1,079 · cited 1×
“…to see what one expects to see (eg, in studies where the examiner was not blinded to the patients ’ health status or treatment); publication bias describes the fact that results not compatible with the original hypothesis have a lesser chance to be submitted or accepted for publication (116).”
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“…refer to Supplementary Table S1 for more data on the effect of GLP-1 receptor agonists on gastric emptying in subjects with type 2 diabetes and obesity. imprecise measurement techniques (31) like the paracetamol (acetaminophen) absorption technique, which continues to be used extensively (32-34).”
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021 · cited 1×
“While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through both parasympathetic (vagal) afferents and direct central nervous stimulation (85-87).”
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“Accordingly, a possible mechanism of action of GLP-1 RAs to reduce appetite and energy intake may involve interaction with neurons in the hypothalamus either directly (66, 67) or via the nodose ganglion (68), rather than a secondary consequence of slowing gastric emptying.”
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 1×
“This dose-dependent slowing of gastric emptying represents a major mechanism contributing to PPG lowering by exogenous GLP-1 and, in healthy humans, “ outweighs ” its insulinotropic effects such that postprandial insulin secretory responses are suppressed rather than stimulated (15, 16).”
Self-citationVantrappen, G., Janssens, J., Hellemans, J., & Ghoos, Y. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108740 · Cited by 815 · cited 1×
“…phase 3 of this complex, which is composed of pressure waves often originating in the stomach and propagated segment by segment toward the duodenum and jejunum (108), which is thought to clear the remnants of the preceding meal including indigestible gastric content from the stomach (108, 109).”
Clinical Significance of Pulmonary Aspiration during the Perioperative Period
Warner, M. A., Warner, M. E., & Weber, J. G. (1993) · Anesthesiology · doi:10.1097/00000542-199301000-00010 · Cited by 808 · cited 1×
“This is a rare complication of general anesthesia, with an incidence of approximately 1 per 3000 elective surgery cases, resulting in death in approximately 1 per 70 000 cases (106).”
Research works printed but not linked: 2
- Schick, 1992, Glucagon-like peptide (GLP)-1(7-36)-amide: a central suppressor of food intake in rats (abstract), Gastroenterol, 102, A756
- Code, 1974, Proceedings of the Fourth International Symposium on Gastrointestinal Motility, 631
Cited by
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
HOCKING, S. L., Scott, D. A., Remedios, M. L., Horowitz, M., Story, D., Greenfield, J. R., Boussioutas, A., Devereaux, B., Andrikopoulos, S., Shaw, J. E., et al. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x251355288 · Cited by 70
Self-citationUllah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
“The maximum duration of any of the few studies in which a good technique has been used to quantify emptying (usually scintigraphy) is 16 weeks, and while the magnitude of the delay in emptying at that time point was not as marked as at 5 weeks, it was substantial in some cases (47).”
Self-citationCedirian, S., Donati, M., Rapparini, L., Pampaloni, F., Plaça, M. L., Sgarzani, R., Negosanti, L., Raschi, E., & Starace, M. V. R. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01537-5 · Cited by 27
Metadata
- Authors
- Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A.
- Affiliations
- Royal Adelaide Hospital (AU)
- St. Josef-Hospital (DE)
- The University of Adelaide (AU)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Nauck, Michael A
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2024-10-17
- Volume
- 110
- Issue
- 1
- Pages
- 1-15
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC11651700
- OpenAlex
- W4403479516
- Cited by
- 157
- References
- 120
- Citations by year
- 2026: 110 · 2025: 45 · 2024: 2
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Funders
- Mary Overton postdoctoral fellowship
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
- Keywords
- GLP-1 receptor agonists, tirzepatide, delayed gastric emptying, pulmonary aspiration, upper gastrointestinal endoscopy, periprocedural management, type 2 diabetes, obesity, tachyphylaxis, prokinetic agents, erythromycin, point-of-care ultrasound, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Emptying, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. https://app.cochat.ai/papers/10.1210/clinem/dgae719
- The paper
- Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.